Evidence map›Paper›PMID 30850011›Full record

Trial reportBreast cancer research : BCR2019

Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.

Carrie B Hruska, Katie N Hunt, Amy Lynn Conners, Jennifer R Geske, Kathleen R Brandt, Amy C Degnim, Celine M Vachon, Michael K O'Connor, Deborah J Rhodes

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02979301 (Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02979301 nacompletednot on this map

Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging

TypeinterventionalSponsorMayo ClinicRan2017 to 2018Enrolled22ConditionsHigh Background Uptake on MBIArmsTamoxifen
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Advances and Future Directions in Molecular Breast Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Carrie B HruskaDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. hruska.carrie@mayo.edu.ORCID 0000-0002-6195-5201
Katie N HuntDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Amy Lynn ConnersDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jennifer R GeskeDepartment of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Kathleen R BrandtDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Amy C DegnimDepartment of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Celine M VachonDepartment of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Michael K O'ConnorDepartment of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Deborah J RhodesDepartment of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Mayo Clinic · US

Funding

Background parenchymal uptake (BPU) on molecular breast imaging as a novel breast cancer risk factorR21CA197752 · NCI · MAYO CLINIC ROCHESTER · PI HRUSKA, CARRIE B · 2015 to 2016
$380k
NCI NIH HHS R21 CA197752
6 · The paper itself

Abstract

backgroundHigh background parenchymal uptake (BPU) on molecular breast imaging (MBI) has been identified as a breast cancer risk factor. We explored the feasibility of offering a short-term intervention of low-dose oral tamoxifen to women with high BPU and examined whether this intervention would reduce BPU.

methodsWomen with a history of high BPU and no breast cancer history were invited to the study. Participants had an MBI exam, followed by 30 days of low-dose oral tamoxifen at either 5 mg or 10 mg/day, and a post-tamoxifen MBI exam. BPU on pre- and post-tamoxifen MBI exams was quantitatively assessed as the ratio of average counts in breast fibroglandular tissue vs. average counts in subcutaneous fat. Pre-tamoxifen and post-tamoxifen BPU were compared with paired t tests.

resultsOf 47 women invited, 22 enrolled and 21 completed the study (10 taking 5 mg tamoxifen, 11 taking 10 mg tamoxifen). Mean age was 47.7 years (range 41-56 years). After 30 days low-dose tamoxifen, 8 of 21 women (38%) showed a decline in BPU, defined as a decrease from the pre-tamoxifen MBI of at least 15%; 11 of 21 (52%) had no change in BPU (within ± 15%); 2 of 21 (10%) had an increase in BPU of greater than 15%. Overall, the average post-tamoxifen BPU was not significantly different from pre-tamoxifen BPU (1.34 post vs. 1.43 pre, p = 0.11). However, among women taking 10 mg tamoxifen, 5 of 11 (45%) showed a decline in BPU; average BPU was 1.19 post-tamoxifen vs. 1.34 pre-tamoxifen (p = 0.005). In women taking 5 mg tamoxifen, 2 of 10 (20%) showed a decline in BPU; average BPU was 1.51 post-tamoxifen vs.1.53 pre-tamoxifen (p = 0.99).

conclusionsShort-term intervention with low-dose tamoxifen may reduce high BPU on MBI for some patients. Our preliminary findings suggest that 10 mg tamoxifen per day may be more effective than 5 mg for inducing declines in BPU within 30 days. Given the variability in BPU response to tamoxifen observed among study participants, future study is warranted to determine if BPU response could predict the effectiveness of tamoxifen for breast cancer risk reduction within an individual.

trial registrationClinicalTrials.gov NCT02979301 . Registered 01 December 2016.

Indexed as

Administration, OralAdultBreastBreast DensityBreast NeoplasmsFeasibility StudiesFemaleGamma CamerasHumansMammographyMiddle AgedMolecular ImagingPilot ProjectsProspective StudiesRadionuclide ImagingRadiopharmaceuticalsRadiopharmaceuticalsTamoxifenTechnetium Tc 99m SestamibiBackground parenchymal uptakeMolecular breast imagingTamoxifenTc-99m sestamibi

Identifiers

PMID30850011
PMCPMC6408779
OpenAlexW2937880799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.